These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 29280500)

  • 41. Characteristics of two alternative schizophrenia remission definitions: relationship to clinical and quality of life outcomes.
    Dunayevich E; Sethuraman G; Enerson M; Taylor CC; Lin D
    Schizophr Res; 2006 Sep; 86(1-3):300-8. PubMed ID: 16860974
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application.
    Leucht S
    J Clin Psychiatry; 2014; 75 Suppl 1():8-14. PubMed ID: 24581453
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Influencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorder.
    Schennach-Wolff R; Meyer S; Seemüller F; Jäger M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Klingberg S; Gastpar M; Möller HJ; Riedel M
    J Psychiatr Res; 2011 Dec; 45(12):1639-47. PubMed ID: 21862035
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Aripiprazole Once-Monthly in the Treatment of Acute Psychotic Episodes in Schizophrenia: Post Hoc Analysis of Positive and Negative Syndrome Scale Marder Factor Scores.
    Ismail Z; Peters-Strickland T; Miguelez M; Baker RA; Hertel P; Eramo A; Jin N; Perry P; Sanchez R; McQuade RD; Kane JM
    J Clin Psychopharmacol; 2017 Jun; 37(3):347-350. PubMed ID: 28383362
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial.
    Loebel A; Cucchiaro J; Sarma K; Xu L; Hsu C; Kalali AH; Pikalov A; Potkin SG
    Schizophr Res; 2013 Apr; 145(1-3):101-9. PubMed ID: 23415311
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia.
    Harvey RC; James AC; Shields GE
    CNS Drugs; 2016 Jan; 30(1):27-39. PubMed ID: 26801655
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The relationship between Positive and Negative Syndrome Scale (PANSS) schizophrenia severity scores and risk for hospitalization: an analysis of the CATIE Schizophrenia Trial.
    Glick HA; Li P; Harvey PD
    Schizophr Res; 2015 Aug; 166(1-3):110-4. PubMed ID: 26044113
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia.
    Davidson M; Saoud J; Staner C; Noel N; Luthringer E; Werner S; Reilly J; Schaffhauser JY; Rabinowitz J; Weiser M; Luthringer R
    Am J Psychiatry; 2017 Dec; 174(12):1195-1202. PubMed ID: 28750582
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: part II: the use of subscales of the PANSS score.
    Pilla Reddy V; Kozielska M; Suleiman AA; Johnson M; Vermeulen A; Liu J; de Greef R; Groothuis GM; Danhof M; Proost JH
    Schizophr Res; 2013 May; 146(1-3):153-61. PubMed ID: 23473811
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia.
    Citrome L; Du Y; Risinger R; Stankovic S; Claxton A; Zummo J; Bose A; Silverman BL; Ehrich EW
    Int Clin Psychopharmacol; 2016 Mar; 31(2):69-75. PubMed ID: 26517202
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia.
    Kinon BJ; Chen L; Ascher-Svanum H; Stauffer VL; Kollack-Walker S; Sniadecki JL; Kane JM
    Schizophr Res; 2008 Jul; 102(1-3):230-40. PubMed ID: 18423985
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
    Lane HY; Chang YC; Liu YC; Chiu CC; Tsai GE
    Arch Gen Psychiatry; 2005 Nov; 62(11):1196-204. PubMed ID: 16275807
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Standardized remission criteria in schizophrenia: descriptive validity and comparability with previously used outcome measures.
    Jäger M; Messer T; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Buchkremer G; Gastpar M; Riedel M; Bottlender R; Strauss A; Möller HJ
    Pharmacopsychiatry; 2008 Sep; 41(5):190-5. PubMed ID: 18763221
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Volume increases in putamen associated with positive symptom reduction in previously drug-naive schizophrenia after 6 weeks antipsychotic treatment.
    Li M; Chen Z; Deng W; He Z; Wang Q; Jiang L; Ma X; Wang Y; Chua SE; Cheung C; McAlonan GM; Sham PC; Collier DA; Gong Q; Li T
    Psychol Med; 2012 Jul; 42(7):1475-83. PubMed ID: 22030695
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A prospective 12-week study of quetiapine in adolescents with schizophrenia spectrum disorders.
    Schimmelmann BG; Mehler-Wex C; Lambert M; Schulze-zur-Wiesch C; Koch E; Flechtner HH; Gierow B; Maier J; Meyer E; Schulte-Markwort M
    J Child Adolesc Psychopharmacol; 2007 Dec; 17(6):768-78. PubMed ID: 18315449
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Optimal thresholds of early response to atypical antipsychotics: application of signal detection methods.
    Chen L; Ascher-Svanum H; Stauffer V; Kinon BJ; Kollack-Walker S; Ruberg S
    Schizophr Res; 2009 Aug; 113(1):34-40. PubMed ID: 19564097
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Early improvements of individual symptoms as a predictor of treatment response to asenapine in patients with schizophrenia.
    Ogyu K; Noda Y; Yoshida K; Kurose S; Masuda F; Mimura Y; Nishida H; Plitman E; Tarumi R; Tsugawa S; Wada M; Miyazaki T; Uchida H; Graff-Guerrero A; Mimura M; Nakajima S
    Neuropsychopharmacol Rep; 2020 Jun; 40(2):138-149. PubMed ID: 32180369
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical relevance of findings in trials of antipsychotics: systematic review.
    Lepping P; Sambhi RS; Whittington R; Lane S; Poole R
    Br J Psychiatry; 2011 May; 198(5):341-5. PubMed ID: 21525517
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Symptom rating scales and outcome in schizophrenia.
    Mortimer AM
    Br J Psychiatry Suppl; 2007 Aug; 50():s7-14. PubMed ID: 18019038
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Brief Questionnaire Derived from PANSS Using a General Probability Model to Assess and Monitor the Clinical Features of Schizophrenia.
    Ji S; Li A; Wu K; Deng C; Dong F; Li L; Zhou T; Yue W; Wang CY; Lu W
    Pharmacopsychiatry; 2016 May; 49(3):117-23. PubMed ID: 26808834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.